Scandion Oncology udvikler anti-cancer lægemidler

26 June 2019 - 17:36
Scandion Oncology udvikler lægemidler, som kan blokere eller omgå resistens overfor anti-cancer lægemidler. Administrerende direktør Nils præsenterer firmaet for investorer....
Spotlight (Sweden)
Scandion Oncology A/S
Scandion is a biotechnology company. The company develops pharmaceuticals for the treatment of cancer containing drug-resistant cell clones. The leading product of the company, SCO-101, has shown to improve the effect of certain standard cancer treatments during preclinical studies. The head office of the company is located in Copenhagen....
Learn more about company

We use cookies to make your experience using IPOhub better. By using our site you agree to our use of cookies. Learn More

Create Your FREE Account to stay Up To Date